Publication: General review Tumor-Agnostic Therapies

Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation

Cancer treatment is evolving from organ-based classification toward biomarker-driven precision medicine, culminating in the development of tumor-agnostic therapies approved based on molecular characteristics, irrespective of tumor origin. Since the US Food and Drug Administration's landmark 2017 approval of pembrolizumab for microsatellite instability-high tumors, nine tumor-agnostic drugs have been approved, offering unprecedented treatment options for patients with rare cancers and actionable genomic alterations. However, this scientific breakthrough has revealed profound global implementation challenges.